Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia
Today, in the era of precision medicine, the determination of genomic instability or other potentially targetable mutations, along with BRCA 1 and BRCA 2, is a crucial component of the diagnosis and treatment management of advanced ovarian cancer. Advanced technologies such as next-generation sequen...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/12/7/1176 |
| _version_ | 1797405884525051904 |
|---|---|
| author | Dora Čerina Višnja Matković Kristina Katić Ingrid Belac Lovasić Robert Šeparović Ivana Canjko Žarko Bajić Eduard Vrdoljak |
| author_facet | Dora Čerina Višnja Matković Kristina Katić Ingrid Belac Lovasić Robert Šeparović Ivana Canjko Žarko Bajić Eduard Vrdoljak |
| author_sort | Dora Čerina |
| collection | DOAJ |
| description | Today, in the era of precision medicine, the determination of genomic instability or other potentially targetable mutations, along with BRCA 1 and BRCA 2, is a crucial component of the diagnosis and treatment management of advanced ovarian cancer. Advanced technologies such as next-generation sequencing (NGS) have enabled comprehensive genomic profiling (CGP) analysis to become more feasible for routine use in daily clinical work. Here, we present the results for the first two years of an analysis of patients with advanced ovarian cancer on a national level. The aim was to establish the position of CGP in the daily clinical practice of treating ovarian cancer. We performed a multicenter, retrospective, cross-sectional analysis on the total population of Croatian patients who were newly diagnosed with locally advanced or metastatic ovarian cancer or whose initial disease had progressed from 1 January 2020 to 1 December 2021, and whose tumors underwent CGP analysis. All 86 patients (100%) analyzed with CGP had at least one genomic alteration (GA). The median LOH was 14.6 (IQR 6.8–21.7), with 35 patients (41%) having an LOH ≥ 16. We found BRCA-positive status in 22 patients (26%). Conventional testing, which detects only BRCA mutations, would have opted for therapy with PARP inhibitors in 22 (26%) of our patients. However, CGP revealed the need for PARP inhibitors in 35 patients (41%). The results identified a significantly higher number of women who would achieve a possible benefit from targeted therapy. Hence, we believe that CGP should be a backbone diagnostic tool in the management of ovarian cancer. |
| first_indexed | 2024-03-09T03:16:41Z |
| format | Article |
| id | doaj.art-22e54795d5284118a83a11089ac95a9e |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-09T03:16:41Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-22e54795d5284118a83a11089ac95a9e2023-12-03T15:17:07ZengMDPI AGJournal of Personalized Medicine2075-44262022-07-01127117610.3390/jpm12071176Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from CroatiaDora Čerina0Višnja Matković1Kristina Katić2Ingrid Belac Lovasić3Robert Šeparović4Ivana Canjko5Žarko Bajić6Eduard Vrdoljak7Department of Oncology, University Hospital Center Split, School of Medicine, University of Split, 21 000 Split, CroatiaDepartment of Gynecologic Oncology, University Hospital Center Zagreb, 10 000 Zagreb, CroatiaDepartment of Gynecologic Oncology, University Hospital Center Zagreb, 10 000 Zagreb, CroatiaDepartment of Radiotherapy and Oncology, University Hospital Center Rijeka, 51 000 Rijeka, CroatiaDepartment of Medical Oncology, Division of Medical Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Center, 10 000 Zagreb, CroatiaDepartment of Radiotherapy and Oncology, University Hospital Center Osijek, 31 000 Osijek, CroatiaResearch Unit “Dr. Mirko Grmek”, University Psychiatric Hospital “Sveti Ivan”, Jankomir 11, 10 000 Zagreb, CroatiaDepartment of Oncology, University Hospital Center Split, School of Medicine, University of Split, 21 000 Split, CroatiaToday, in the era of precision medicine, the determination of genomic instability or other potentially targetable mutations, along with BRCA 1 and BRCA 2, is a crucial component of the diagnosis and treatment management of advanced ovarian cancer. Advanced technologies such as next-generation sequencing (NGS) have enabled comprehensive genomic profiling (CGP) analysis to become more feasible for routine use in daily clinical work. Here, we present the results for the first two years of an analysis of patients with advanced ovarian cancer on a national level. The aim was to establish the position of CGP in the daily clinical practice of treating ovarian cancer. We performed a multicenter, retrospective, cross-sectional analysis on the total population of Croatian patients who were newly diagnosed with locally advanced or metastatic ovarian cancer or whose initial disease had progressed from 1 January 2020 to 1 December 2021, and whose tumors underwent CGP analysis. All 86 patients (100%) analyzed with CGP had at least one genomic alteration (GA). The median LOH was 14.6 (IQR 6.8–21.7), with 35 patients (41%) having an LOH ≥ 16. We found BRCA-positive status in 22 patients (26%). Conventional testing, which detects only BRCA mutations, would have opted for therapy with PARP inhibitors in 22 (26%) of our patients. However, CGP revealed the need for PARP inhibitors in 35 patients (41%). The results identified a significantly higher number of women who would achieve a possible benefit from targeted therapy. Hence, we believe that CGP should be a backbone diagnostic tool in the management of ovarian cancer.https://www.mdpi.com/2075-4426/12/7/1176advanced ovarian cancercomprehensive genomic profilingtargeted therapyprecision medicine |
| spellingShingle | Dora Čerina Višnja Matković Kristina Katić Ingrid Belac Lovasić Robert Šeparović Ivana Canjko Žarko Bajić Eduard Vrdoljak Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia Journal of Personalized Medicine advanced ovarian cancer comprehensive genomic profiling targeted therapy precision medicine |
| title | Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia |
| title_full | Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia |
| title_fullStr | Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia |
| title_full_unstemmed | Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia |
| title_short | Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia |
| title_sort | comprehensive genomic profiling in the management of ovarian cancer national results from croatia |
| topic | advanced ovarian cancer comprehensive genomic profiling targeted therapy precision medicine |
| url | https://www.mdpi.com/2075-4426/12/7/1176 |
| work_keys_str_mv | AT doracerina comprehensivegenomicprofilinginthemanagementofovariancancernationalresultsfromcroatia AT visnjamatkovic comprehensivegenomicprofilinginthemanagementofovariancancernationalresultsfromcroatia AT kristinakatic comprehensivegenomicprofilinginthemanagementofovariancancernationalresultsfromcroatia AT ingridbelaclovasic comprehensivegenomicprofilinginthemanagementofovariancancernationalresultsfromcroatia AT robertseparovic comprehensivegenomicprofilinginthemanagementofovariancancernationalresultsfromcroatia AT ivanacanjko comprehensivegenomicprofilinginthemanagementofovariancancernationalresultsfromcroatia AT zarkobajic comprehensivegenomicprofilinginthemanagementofovariancancernationalresultsfromcroatia AT eduardvrdoljak comprehensivegenomicprofilinginthemanagementofovariancancernationalresultsfromcroatia |